2200 Bridge Parkway
12 articles with Acerta Pharma
26 months median duration of response achieved in relapsed or refractory mantle cell lymphoma at updated two-year analysis
AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting
27 scientific presentations, including long-term data from CALQUENCE in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukemia
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
H. Gilbert Welch, a health care policy scholar at Dartmouth College, reportedly plagiarized part of the contents in a 2016 New England Journal of Medicine article. The article focused on breast cancer screening and the increased likelihood of tumors being overdiagnosed.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
AstraZeneca's CALQUENCE (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta and demonstrate the safety profile and efficacy of CALQUENCE in the management of previously-treated mantle cell lymphoma (MCL).
The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta.
10/25/2017Incyte has been at the forefront of the IDO race with its candidate epacadostat.
AstraZeneca PLC Takes 55% Stake in Acerta Pharma for $4 Billion with Option to Buy Rest for Another $3 Billion